The FDA has 4 standard acceleration programs

• Priority Review

• Breakthrough Therapy

• Accelerated Approval

• Fast Track

If any trial for the drug AOH1996 is put on one or more of these tracks the market will resolve yes.

The drug must actually be accepted into one of these accelerated programs, if e.g. the drug company doesn't make the necessary request, the market will resolve no even if it "would have" been approved by the FDA.

Acceptance into these programs is all reported unambiguously by the FDA, e.g.

https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals FDA reports will be the truth source.

Setting the close date 2 years out, as that agrees with the approval timeline market. Will extend iff there is material pending progress, e.g. company has filed paperwork for one of the above.